Is MIB-626 legal in Australia?

The only NMN product with a real randomised trial programme: three placebo-controlled trials totalling about 104 participants, all of which measured blood NAD and safety. It raised blood NAD substantially every time. It did not change muscle strength, aerobic capacity, insulin sensitivity, liver fat, or any marker of kidney injury or inflammation in hospitalised patients.

MIB-626 is beta-nicotinamide mononucleotide. The molecule is the same one sold in supplement capsules.

Mechanism: The active molecule is beta-nicotinamide mononucleotide, which enters NAD synthesis one step below nicotinamide riboside: NMN is adenylylated by NMNAT enzymes directly to NAD, bypassing the NAMPT step that limits nicotinamide. The proprietary element is formulation rather than pharmacology, a defined microcrystalline polymorph intended to give reproducible, pharmaceutical-grade exposure, which is what allows dose-ranging and regulatory filing in a way a variable supplement powder does not.

Regulatory history: An investigational drug in the United States, developed under an IND by Metro International Biotech. It is not approved for any indication and is not the same regulatory object as NMN sold as a dietary supplement, although the molecule is identical. The existence of that IND is what triggered FDA's 2022 determination excluding NMN from the dietary supplement definition, a determination FDA reversed in September 2025.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for MIB-626 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.